Latest Information Update: 10 Mar 2004
At a glance
- Originator AstraZeneca
- Mechanism of Action Neurokinin 2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 30 Jan 2004 Discontinued - Preclinical for Overactive bladder in Europe (unspecified route)
- 20 Feb 2001 New profile
- 20 Feb 2001 Preclinical development for Overactive bladder in Europe (Unknown route)